Email Page Print Page

BDSI®'s Privacy Policy


This notice describes the privacy policy of BioDelivery Sciences International, Inc. ("BDSI®"). By visiting and using, you agree to the practices described in this Privacy Notice. Please carefully read our Terms of Use and our Privacy Policy before using our website. By using BDSI®'s website, you agree to follow and be bound by our Terms of Use and our Privacy Policy without modification, and as the same may be modified by BDSI® in its discretion from time to time.


Because we will continue to seek to improve the services and features we provide on our website, BDSI® reserves the right to amendment, modify or update this Privacy Policy in its discretion at any time and without notice. Any changes or updates will be effective immediately upon posting to this website. For that reason, we encourage you to review this Privacy Policy periodically.


Information Sharing

BDSI® is the sole owner of any information collected on this website. We will not sell, share, or rent this information to others in ways different from what is disclosed in this statement. BDSI® may collect information from our users at several different points on our website.


We intend to give you as much control as reasonably possible over your personal information. In general, you can visit without telling us who you are or revealing any information about yourself. There are times when we may need information from you in order to respond to your needs. If you choose to give us personal information we may use that information to correspond with you or provide you with requested materials. If you tell us that you do not wish to have this information used as a basis for further contact, we will respect your wishes. We may analyze this data for trends and statistics, but we will not share the information with third parties unless necessary to provide services to you or as may be required by law.


Logging Site Traffic

BDSI® maintains log files of the site traffic on We do not link any information gathered in these log files to personal information. Log files are used to manage traffic loads, identify the content most commonly accessed, and information technology requirements for providing reliable service. Information collected includes IP addresses and browser types.



"Cookies" can be used to provide you with tailored information from a website. This website may use "cookies" so that we can better serve you when you return to our site. A cookie is a text file that is placed on your hard disk by a Web server. Cookies are uniquely assigned to you, and can only be read by a Web server in the domain that issued the cookie to you. Cookies cannot be used to run programs or deliver viruses to your computer.


Most Web browsers automatically accept cookies, but you can usually modify your browser setting to decline cookies. If you choose to decline cookies, you may not be able to fully utilize all features of this website. You have the ability to delete cookie files from your hard drive at any time.

contact information

Corporate Headquarters
801 Corporate Center Drive, Suite 210
Raleigh, NC 27607
Tel: 919 582 9050
Fax: 919 582 9051

Business Development Contact
Al Medwar
801 Corporate Center Drive, Suite 210
Raleigh, NC 27607
Tel: 919 582 9050
Fax: 919 582 9051

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces Preferred Formulary Status for BUNAVAIL on Texas Medicaid
BUNAVAIL moved from non-formulary to preferred status

BioDelivery Sciences Announces Additions to its Board of Directors
Timothy C. Tyson joins BDSI's board as an independent member with over 30 years of pharmaceutical experience

BioDelivery Sciences Cites Impressive Number of Physicians Granted Waiver to Increase Patient Limit for Opioid Dependence Treatment Following Recent HHS Rule
SAMHSA Reports 1,665 Clinicians Granted Waivers at the Increased Limit as of This Week

BioDelivery Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

BioDelivery Sciences Announces Three New Managed Care Agreements; Further Enhancing Access to BUNAVAIL
New contracts improve BUNAVAIL formulary status and give BUNAVAIL access to approximately 200,000 additional prescriptions for buprenorphine products for opioid dependence annually